
Release date: 2026-05-28 15:32:42 Article From: Lucius Laos Recommended: 33
The standard recommended dosage of Tivozanib is one 1340 microgram capsule taken once daily for 21 consecutive days (3 weeks), followed by a 7-day (1 week) break. This 4-week cycle is then repeated. Treatment typically continues as long as the drug is effective and the patient does not experience unacceptable side effects. The capsule should be swallowed whole with a full glass of water, with or without food. Do not chew, dissolve, or open the capsule. Your doctor will regularly assess your condition and adjust the regimen as necessary.
If severe side effects occur, your doctor may interrupt treatment or reduce the dose to one 890 microgram capsule taken once daily for 21 days, followed by a 7-day break, also in a 4-week cycle. For patients with liver problems, your doctor may reduce the dosing frequency to once every other day (i.e., one 1340 microgram capsule every other day). Side effects such as hand-foot syndrome and hypertension may also lead to dose reduction or temporary interruption. If surgery is required, your doctor may advise you to temporarily stop taking Fotivda because it may affect wound healing.
If you forget to take a capsule, do not take a missed dose; simply take the next dose at the regular time. Never take a double dose to make up for a missed one. If you vomit after taking a dose, do not take another capsule; just take the next dose at the regular time. If you take more than one capsule per day, tell your doctor immediately. Overdose is more likely to cause side effects, particularly hypertension. If you experience symptoms of high blood pressure such as confusion, altered mental status, or headache, seek medical attention immediately. Do not stop taking the medication without your doctor's permission, as this may worsen your condition.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:3842025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:5782024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:3622025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:3782025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:3592025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:4262025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:3492025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:3252025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643